Lacasta Delia, Reina Ramses, Ruiz de Arcaute Marta, Ferrer Luis Miguel, Benito Alfredo Angel, Tejedor Maria Teresa, Echeverria Irache, Ruiz Hector, Martinez Cardenas Silvia, Windsor Peter Andrew
Animal Pathology Department, Instituto Agroalimentario de Aragón-IA2 (Universidad de Zaragoza-CITA), Veterinary Faculty of Zaragoza, Zaragoza, 50013, Spain.
Instituto de Agrobiotecnología (CSIC-Gobierno de Navarra), Mutilva, 31192, Navarra, Spain.
Vet Med (Auckl). 2021 Jun 9;12:149-158. doi: 10.2147/VMRR.S306355. eCollection 2021.
Orf is a highly contagious eruptive viral disease of the skin and mucosa of sheep and goats. Although vaccination with live or attenuated orf virus is the preferred option for disease control, the vaccine is unavailable in many countries. Treatment of orf lesions involves standard hygiene and in numerous cases, management of presumptive secondary infections with antibiotics, increasing risks of antimicrobial resistance (AMR). The wound dressing formulation Tri-Solfen containing two local anaesthetics (lignocaine and bupivacaine), adrenaline and an antiseptic (cetrimide) in a gel formulation was developed for pain relief in sheep undergoing surgical husbandry procedures in Australia. Recently, TS therapy was found to reduce suffering and enhance recovery in cattle and buffalo with oral and skin lesions due to foot-and-mouth disease (FMD) virus infection. It was noted that TS has a low pH and is potentially viricidal, potentially aiding disease control.
One-month-old lambs (n=14), naturally infected with orf, were recruited from a farm during a natural outbreak of the disease. The animals were selected at the early stages of the infection and randomly divided into two cohorts: Group A (n=11) treated with the topical wound gel formulation (TS); and Group B (n=3) an untreated control group. Swabs were obtained before treatment (T0) and on days one (T1), 3 (T2) and 5 (T3) post-treatment, then submitted to direct DNA extraction with real-time PCR quantification, plus incubation with primary tissue cultures from ovine skin fibroblasts (OSF) and T-immortalized goat embryonic fibroblasts (TIGEF).
Although no significant differences were found in the clinical progression of the lesions and PCR quantification (p=0.722) between these small cohorts, there was a significant difference (p<0.05) in reduction in infective viral load between the groups when assessed in OSF cell cultures between T0 and T3.
These preliminary findings suggest that treatment of early stage lesions with this TS may reduce the infective viral load present in orf lesions.
羊痘是绵羊和山羊皮肤及黏膜的一种高度传染性的爆发性病毒病。尽管使用活的或减毒的羊痘病毒进行疫苗接种是疾病控制的首选方法,但该疫苗在许多国家无法获得。羊痘病变的治疗包括标准卫生措施,在许多情况下,还包括使用抗生素处理假定的继发感染,这增加了抗菌药物耐药性(AMR)的风险。伤口敷料制剂Tri-Solfen是一种凝胶制剂,含有两种局部麻醉剂(利多卡因和布比卡因)、肾上腺素和一种防腐剂(西曲溴铵),用于缓解澳大利亚接受外科饲养程序的绵羊的疼痛。最近,发现Tri-Solfen疗法可减轻口蹄疫(FMD)病毒感染引起的牛和水牛口腔及皮肤病变的痛苦并促进恢复。值得注意的是,Tri-Solfen的pH值较低,可能具有杀病毒作用,这可能有助于疾病控制。
在一次自然爆发的疾病期间,从一个农场招募了14只自然感染羊痘的1月龄羔羊。这些动物在感染的早期阶段被挑选出来,并随机分为两组:A组(n = 11)用局部伤口凝胶制剂(Tri-Solfen)治疗;B组(n = 3)为未治疗的对照组。在治疗前(T0)以及治疗后第1天(T1)、3天(T2)和5天(T3)采集拭子,然后进行直接DNA提取并进行实时PCR定量,再与绵羊皮肤成纤维细胞(OSF)和永生化山羊胚胎成纤维细胞(TIGEF)的原代组织培养物一起孵育。
尽管在这些小样本队列之间,病变的临床进展和PCR定量结果没有显著差异(p = 0.722),但在T0和T3之间通过OSF细胞培养评估时,两组之间的感染性病毒载量降低存在显著差异(p < 0.05)。
这些初步研究结果表明,用这种Tri-Solfen治疗早期病变可能会降低羊痘病变中存在的感染性病毒载量。